Waters Corporation (WAT): Reset Complete or Temporary Rebound?—Can Asia’s Recovery and Instrument Growth Sustain Momentum Over the Coming 3 Years?

$50.00 or $120.00 / year

Waters Corporation delivered a robust Q3, with 4% constant currency revenue growth exceeding expectations by $27.12M, driven by broad-based strength across geographies and segments. A key milestone was the return to instrument growth after seven quarters of decline, supported by a rebound in liquid chromatography (LC) within large pharma. Recurring revenues remained resilient, growing mid- to high-single digits, while adjusted EPS of $2.93 beat estimates by $0.25. Management raised Q4 guidance to 6% growth at the midpoint, reflecting confidence in customer trends despite seasonal caution. Strategically, Waters is capitalizing on growth adjacencies like bioseparations, clinical diagnostics, and PFAS testing, with MaxPeak Premier and GLP-1 adoption as notable drivers. India’s 26% YoY growth and operational efficiencies from its Global Capability Center underpin its competitive edge, while China restructuring efforts mitigate macro uncertainties. However, uneven instrument replacement cycles, industrial softness, and timing of China’s stimulus introduce risks. With incremental clarity needed on LC demand, GLP-1 scaling, and China recovery, pricing and margin expansion offer resilience. As Waters navigates this recovery, the critical question remains: can the company sustain growth and margin momentum over the coming years, particularly in Asia and high-growth adjacencies?

Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures

Scroll to Top